Recombinant Human TL-1A
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Description | TL-1A belongs to the TNF superfamily of ligands. It is expressed predominantly in endothelial cells, and to a lesser extent in placenta, lung, kidney, skeletal muscle, pancreas, small intestine and colon. TL-1A inhibits endothelial cell proliferation and angiogenesis, and has been shown to induce NFkB activation, caspase activity, and apoptosis in responding cell lines. TL-1A interacts with TNFRSF25/DR3 receptor, but can also bind to a decoy receptor TNFRSF21/DR6. Recombinant human TL-1A is a 22.0 kDa polypeptide of 194 amino acid residues. |
---|---|
BiologicalActivity | Determined by its ability to stimulate IFN-γ production by human PBMC using a concentration range of 10.0-100.0 ng/ml. Note: Results may vary with PBMC donors. |
Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
Endotoxin | Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg). |
Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
Storage | -20°C |
Precautions | Recombinant Human TL-1A is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.